A Brazilian multicentre study evaluating pregnancies induced by cabergoline in patients harboring prolactinomas
- 40 Downloads
To evaluate the maternal–fetal outcomes of CAB-induced pregnancies in patients with prolactinoma in a large cohort.
The prevalence of tumor growth, miscarriage, preterm, low birth weight, congenital malformations and impairment in neuropsychological development in children among women treated with CAB were assessed in a Brazilian multicentre retrospective observational study,
We included 194 women with a mean age of 31 (17–45) years, 43.6% presenting microadenomas and 56.4% macroadenomas, at prolactinoma diagnosis. In 233 pregnancies, CAB was withdrawn in 89%, after pregnancy confirmation. Symptoms related to tumor growth occurred in 25 cases, more frequently in macroadenomas. The overall miscarriage rate was 11%, although higher in the subgroup of patients with CAB maintainance after pregnancy confirmation (38% vs. 7.5%). Amongst the live-birth deliveries, preterm occurred in 12%, low birth weight in 6% and congenital malformations in 4.3%. Neuropsychological development impairment was reported in 7% of cases.
Our findings confirm previous results of safety in maternal and fetal outcomes in CAB-induced pregnancies; nevertheless, CAB maintenance after pregnancy confirmation was associated with higher miscarriage rate; result that must be further confirmed.
KeywordsProlactinoma Pregnancy Dopamine agonist Cabergoline Miscarriage Malformation
No financial support.
Compliance with ethical standards
Conflict of interest
Musolino NRC. received fees as a speaker for Pfizer. Ribeiro-Oliveira Júnior A. received fees as a speaker for Novartis and IPSEN. He is currently an employee of IPSEN Biosciences in the USA, and data was generated before his joining to IPSEN. We certify that nor other co-authors have a conflict of interest as described above that is relevant to the subject matter or materials included in this Work.
- 16.Bigazzi M, Ronga R, Lancranjan I, Ferraro S, Branconi F, Buzzoni P et al (1979) A pregnancy in an acromegalic woman during bromocriptine treatment: effects on growth hormone and prolactin in the maternal, fetal, and amniotic compartments. J Clin Endocrinol Metab 48(1):9–12PubMedCrossRefGoogle Scholar
- 19.Lebbe M, Hubinont C, Bernard P, Maiter D (2010) Outcome of 100 pregnancies initiated under treatment with cabergoline in hyperprolactinaemic women. Clin Endocrinol 73(2):236–242Google Scholar
- 48.Blencowe H, Cousens S, Oestergaard MZ, Chou D, Moller AB, Narwal R et al (2012) National, regional, and worldwide estimates of preterm birth rates in the year 2010 with time trends since 1990 for selected countries: a systematic analysis and implications. Lancet 379(9832):2162–2172PubMedCrossRefGoogle Scholar
- 52.Mitsiakos G (2019) A possible role of GDNF expression by which cabergoline use affects corpus callosum. J Pediatr Neonatal Individ Med 8:e080112Google Scholar